{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:16:44Z","timestamp":1791400604788,"version":"4.3.3"},"reference-count":92,"publisher":"The Endocrine Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,4,1]]},"abstract":"<jats:p>More than 90% of ovarian cancers have been thought to arise from epithelial cells that cover the ovarian surface or, more frequently, line subserosal cysts. Recent studies suggest that histologically similar cancers can arise from the fimbriae of Fallopian tubes and from deposits of endometriosis. Different histotypes are observed that resemble epithelial cells from the normal Fallopian tube (serous), endometrium (endometrioid), cervical glands (mucinous), and vaginal rests (clear cell) and that share expression of relevant HOX genes which drive normal gynecological differentiation. Two groups of epithelial ovarian cancers have been distinguished: type I low-grade cancers that present in early stage, grow slowly, and resist conventional chemotherapy but may respond to hormonal manipulation; and type II high-grade cancers that are generally diagnosed in advanced stage and grow aggressively but respond to chemotherapy. Type I cancers have wild-type p53 and BRCA1\/2, but have frequent mutations of Ras and Raf as well as expression of IGFR and activation of the phosphatidylinositol-3-kinase (PI3K) pathway. Virtually all type II cancers have mutations of p53, and almost half have mutation or dysfunction of BRCA1\/2, but other mutations are rare, and oncogenesis appears to be driven by amplification of several growth-regulatory genes that activate the Ras\/MAPK and PI3K pathways. Cytoreductive surgery and combination chemotherapy with platinum compounds and taxanes have improved 5-yr survival, but less than 40% of all stages can be cured. Novel therapies are being developed that target high-grade serous cancer cells with PI3Kness or BRCAness as well as the tumor vasculature. Both in silico and animal models are needed that more closely resemble type I and type II cancers to facilitate the identification of novel targets and to predict response to combinations of new agents.<\/jats:p>","DOI":"10.1210\/en.2011-2123","type":"journal-article","created":{"date-parts":[[2012,3,15]],"date-time":"2012-03-15T00:19:41Z","timestamp":1331770781000},"page":"1593-1602","source":"Crossref","is-referenced-by-count":236,"title":["Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy"],"prefix":"10.1210","volume":"153","author":[{"given":"Ignacio","family":"Romero","sequence":"first","affiliation":[{"name":"Area Clinica Oncologia Ginecologica (I.R.), Instituto Valenciano de Oncologia, 46009 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Robert C.","family":"Bast","sequence":"first","affiliation":[{"name":"the Department of Experimental Therapeutics (R.C.B.), University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2012,3,13]]},"reference":[{"key":"2020071612032484900_B1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics.","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"2020071612032484900_B2","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/01.AOG.0000216004.22588.ce","article-title":"Incidence and survival rates for female malignant germ cell tumors.","volume":"107","author":"Smith","year":"2006","journal-title":"Obstet Gynecol"},{"key":"2020071612032484900_B3","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nm1230","article-title":"Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract.","volume":"11","author":"Cheng","year":"2005","journal-title":"Nat Med"},{"key":"2020071612032484900_B4","first-page":"161","article-title":"Histologic subtypes of ovarian carcinoma: an overview.","volume":"27","author":"Soslow","year":"2008","journal-title":"Int J Gynecol Pathol"},{"key":"2020071612032484900_B5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/00004347-200001000-00003","article-title":"Histopathologic grading of ovarian carcinoma: a review and proposal.","volume":"19","author":"Silverberg","year":"2000","journal-title":"Int J Gynecol Pathol"},{"key":"2020071612032484900_B6","doi-asserted-by":"crossref","first-page":"e10358","DOI":"10.1371\/journal.pone.0010358","article-title":"Genetic analysis of the early natural history of epithelial ovarian carcinoma.","volume":"5","author":"Pothuri","year":"2010","journal-title":"PLoS One"},{"key":"2020071612032484900_B7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/path.2091","article-title":"A candidate precursor to serous carcinoma that originates in the distal fallopian tube.","volume":"211","author":"Lee","year":"2007","journal-title":"J Pathol"},{"key":"2020071612032484900_B8","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/path.1000","article-title":"Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer.","volume":"195","author":"Piek","year":"2001","journal-title":"J Pathol"},{"key":"2020071612032484900_B9","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference.","volume":"21","author":"Stuart","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"2020071612032484900_B10","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"key":"2020071612032484900_B11","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1200\/JCO.2006.07.9970","article-title":"Early events in the pathogenesis of epithelial ovarian cancer.","volume":"26","author":"Landen","year":"2008","journal-title":"J Clin Oncol"},{"key":"2020071612032484900_B12","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0002-9440(10)63708-X","article-title":"Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.","volume":"164","author":"Shih","year":"2004","journal-title":"Am J Pathol"},{"key":"2020071612032484900_B13","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2644","article-title":"The biology of ovarian cancer: new opportunities for translation.","volume":"9","author":"Bast","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"2020071612032484900_B14","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrc3144","article-title":"Rethinking ovarian cancer: recommendations for improving outcomes.","volume":"11","author":"Vaughan","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"2020071612032484900_B15","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinoma using a two-tier system.","volume":"28","author":"Malpica","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"2020071612032484900_B16","doi-asserted-by":"crossref","first-page":"6432","DOI":"10.1158\/1078-0432.CCR-04-0893","article-title":"Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.","volume":"10","author":"Hsu","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2020071612032484900_B17","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2007.11.013","article-title":"Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.","volume":"108","author":"Schmeler","year":"2008","journal-title":"Gynecol Oncol"},{"key":"2020071612032484900_B18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2009.03.001","article-title":"Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.","volume":"114","author":"Gershenson","year":"2009","journal-title":"Gynecol Oncol"},{"key":"2020071612032484900_B19","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.2004.08.078","article-title":"Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment.","volume":"22","author":"Hess","year":"2004","journal-title":"J Clin Oncol"},{"key":"2020071612032484900_B20","first-page":"281","article-title":"Low proliferation activity may be associated with chemo-resistance in clear cell carcinoma of the ovary.","volume":"100","author":"Itamochi","year":"2002","journal-title":"Obstet Gynecol"},{"key":"2020071612032484900_B21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1081\/CNV-120000361","article-title":"Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival.","volume":"20","author":"Pieretti","year":"2002","journal-title":"Cancer Invest"},{"key":"2020071612032484900_B22","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00004347-200107000-00007","article-title":"k-ras mutation may be an early event in mucinous ovarian tumorigenesis.","volume":"20","author":"Garrett","year":"2001","journal-title":"Int J Gynecol Pathol"},{"key":"2020071612032484900_B23","doi-asserted-by":"crossref","first-page":"6422","DOI":"10.1158\/1078-0432.CCR-05-0508","article-title":"Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.","volume":"11","author":"Zorn","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2020071612032484900_B24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1126\/science.1196333","article-title":"Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.","volume":"330","author":"Jones","year":"2010","journal-title":"Science"},{"key":"2020071612032484900_B25","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","article-title":"ARID1A mutations in endometriosis-associated ovarian carcinomas.","volume":"363","author":"Wiegand","year":"2010","journal-title":"N Engl J Med"},{"key":"2020071612032484900_B26","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma.","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"2020071612032484900_B27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer Statistics 2009.","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"2020071612032484900_B28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ygyno.2005.07.008","article-title":"Who should operate on patients with ovarian cancer? An evidence-based review.","volume":"99","author":"Giede","year":"2005","journal-title":"Gynecol Oncol"},{"key":"2020071612032484900_B29","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/ijgc-00009577-200311001-00002","article-title":"What have we learned from ICON1 and ACTION?","volume":"13","author":"Colombo","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"2020071612032484900_B30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ijgo.2007.11.004","article-title":"History of the FIGO cancer staging system.","volume":"101","author":"Odicino","year":"2008","journal-title":"Int J Gynaecol Obstet"},{"key":"2020071612032484900_B31","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1245\/s10434-009-0357-0","article-title":"Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis.","volume":"16","author":"Harter","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"2020071612032484900_B32","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","article-title":"Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.","volume":"106","author":"Chi","year":"2006","journal-title":"Cancer"},{"key":"2020071612032484900_B33","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","article-title":"Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.","volume":"19","author":"Markman","year":"2001","journal-title":"J Clin Oncol"},{"key":"2020071612032484900_B34","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.","volume":"335","author":"Alberts","year":"1996","journal-title":"N Engl J Med"},{"key":"2020071612032484900_B35","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer.","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"2020071612032484900_B36","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"},{"key":"2020071612032484900_B37","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.","volume":"27","author":"Bookman","year":"2009","journal-title":"J Clin Oncol"},{"key":"2020071612032484900_B38","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/annonc\/mdi147","article-title":"Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study.","volume":"16","author":"Gonz\u00e1lez-Mart\u00edn","year":"2005","journal-title":"Ann Oncol"},{"key":"2020071612032484900_B39","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial.","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"key":"2020071612032484900_B40","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J Clin Oncol"},{"key":"2020071612032484900_B41","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J Clin Oncol"},{"key":"2020071612032484900_B42","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrclinonc.2010.152","article-title":"A new standard combination for recurrent ovarian cancer?","volume":"7","author":"Bast","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"2020071612032484900_B43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","article-title":"Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.","volume":"95","author":"Gordon","year":"2004","journal-title":"Gynecol Oncol"},{"key":"2020071612032484900_B44","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","article-title":"Phase II trial of weekly paclitaxel (80 mg\/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study.","volume":"101","author":"Gynecologic Oncology Group","year":"2006","journal-title":"Gynecol Oncol"},{"key":"2020071612032484900_B45","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.","volume":"15","author":"ten Bokkel Huinink","year":"1997","journal-title":"J Clin Oncol"},{"key":"2020071612032484900_B46","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1023\/A:1008469212268","article-title":"A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.","volume":"9","author":"Friedlander","year":"1998","journal-title":"Ann Oncol"},{"key":"2020071612032484900_B47","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"key":"2020071612032484900_B48","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol"},{"key":"2020071612032484900_B49","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ygyno.2004.08.028","article-title":"A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.","volume":"95","author":"Berkenblit","year":"2004","journal-title":"Gynecol Oncol"},{"key":"2020071612032484900_B50","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.1998.16.2.405","article-title":"Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.","volume":"16","author":"Rose","year":"1998","journal-title":"J Clin Oncol"},{"key":"2020071612032484900_B51","doi-asserted-by":"crossref","first-page":"27371","DOI":"10.1074\/jbc.M103554200","article-title":"Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16.","volume":"276","author":"Yin","year":"2001","journal-title":"J Biol Chem"},{"key":"2020071612032484900_B52","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ygyno.2011.04.032","article-title":"More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis.","volume":"121","author":"Bast","year":"2011","journal-title":"Gynecol Oncol"},{"key":"2020071612032484900_B53","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJM198310133091503","article-title":"A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.","volume":"309","author":"Bast","year":"1983","journal-title":"N Engl J Med"},{"key":"2020071612032484900_B54","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","article-title":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial.","volume":"376","author":"Rustin","year":"2010","journal-title":"Lancet"},{"key":"2020071612032484900_B55","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1002\/cncr.25203","article-title":"Commentary: CA125 and the detection of recurrent ovarian cancer: A reasonably accurate biomarker for a difficult disease.","volume":"116","author":"Bast","year":"2010","journal-title":"Cancer"},{"key":"2020071612032484900_B56","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1471-0528.1990.tb02448.x","article-title":"A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer.","volume":"97","author":"Jacobs","year":"1990","journal-title":"Br J Obstet Gynaecol"},{"key":"2020071612032484900_B57","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/AOG.0b013e31821b5118","article-title":"Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors.","volume":"117","author":"Ueland","year":"2011","journal-title":"Obstet Gynecol"},{"key":"2020071612032484900_B58","doi-asserted-by":"crossref","first-page":"228.e1","DOI":"10.1016\/j.ajog.2010.03.043","article-title":"Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass.","volume":"203","author":"Moore","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"2020071612032484900_B59","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/AOG.0b013e318224fce2","article-title":"Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass.","volume":"118","author":"Moore","year":"2011","journal-title":"Obstet Gynecol"},{"key":"2020071612032484900_B60","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1470-2045(09)70026-9","article-title":"Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).","volume":"10","author":"Menon","year":"2009","journal-title":"Lancet Oncol"},{"key":"2020071612032484900_B61","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.5003","article-title":"A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA).","volume":"28","author":"Lu","year":"2010","journal-title":"J Clin Oncol"},{"key":"2020071612032484900_B62","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","article-title":"Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.","volume":"18","author":"Muggia","year":"2000","journal-title":"J Clin Oncol"},{"key":"2020071612032484900_B63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"2020071612032484900_B64","first-page":"144","article-title":"Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer.","volume":"13","author":"Piccart","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"2020071612032484900_B65","doi-asserted-by":"crossref","first-page":"5806","DOI":"10.1158\/0008-5472.CAN-11-0025","article-title":"Modulating microtubule stability enhances the cytotoxic response of cancer cells to paclitaxel.","volume":"71","author":"Ahmed","year":"2011","journal-title":"Cancer Res"},{"key":"2020071612032484900_B66","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ccr.2010.06.018","article-title":"SIK2 is a centrosome kinase required for bipolar spindle formation that provides a potential target for therapy in ovarian cancer.","volume":"18","author":"Ahmed","year":"2010","journal-title":"Cancer Cell"},{"key":"2020071612032484900_B67","first-page":"1311","article-title":"Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.","volume":"63","author":"Selvakumaran","year":"2003","journal-title":"Cancer Res"},{"key":"2020071612032484900_B68","first-page":"5299","article-title":"Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer.","volume":"9","author":"Reed","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2020071612032484900_B69","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc1123","article-title":"Ovarian cancer: strategies for overcoming resistance to chemotherapy.","volume":"3","author":"Agarwal","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"2020071612032484900_B70","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of 'BRCAness' in sporadic cancers.","volume":"4","author":"Turner","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"2020071612032484900_B71","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1200\/JCO.2010.28.5791","article-title":"Personalizing therapy for ovarian cancer: BRCAness and beyond.","volume":"28","author":"Bast","year":"2010","journal-title":"J Clin Oncol"},{"key":"2020071612032484900_B72","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2007.11.6905","article-title":"Effect of BRCA1\/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.","volume":"26","author":"Chetrit","year":"2008","journal-title":"J Clin Oncol"},{"key":"2020071612032484900_B73","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1200\/JCO.2008.16.1703","article-title":"\u201cBRCAness\u201d syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.","volume":"26","author":"Tan","year":"2008","journal-title":"J Clin Oncol"},{"key":"2020071612032484900_B74","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ygyno.2005.10.029","article-title":"The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer.","volume":"101","author":"Malander","year":"2006","journal-title":"Gynecol Oncol"},{"key":"2020071612032484900_B75","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/jnci\/djj465","article-title":"Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.","volume":"98","author":"Risch","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"2020071612032484900_B76","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"key":"2020071612032484900_B77","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2407-8-17","article-title":"Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.","volume":"8","author":"Press","year":"2008","journal-title":"BMC Cancer"},{"key":"2020071612032484900_B78","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1200\/JCO.2009.27.2997","article-title":"Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.","volume":"28","author":"Hennessy","year":"2010","journal-title":"J Clin Oncol"},{"key":"2020071612032484900_B79","doi-asserted-by":"crossref","first-page":"23899","DOI":"10.1074\/jbc.C000276200","article-title":"The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin.","volume":"275","author":"Bhattacharyya","year":"2000","journal-title":"J Biol Chem"},{"key":"2020071612032484900_B80","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"key":"2020071612032484900_B81","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/2159-8290.CD-11-0323","article-title":"Dissecting \u201cPI3Kness\u201d: the complexity of personalized therapy for ovarian cancer.","volume":"2","author":"Bast","year":"2012","journal-title":"Cancer Discovery"},{"key":"2020071612032484900_B82","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/gcc.20883","article-title":"Frequent genetic abnormalities of the PI3K\/AKT pathway in primary ovarian cancer predict patient outcome.","volume":"50","author":"Huang","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"key":"2020071612032484900_B83","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/emmm.200900041","article-title":"Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.","volume":"1","author":"Mendes-Pereira","year":"2009","journal-title":"EMBO Mol Med"},{"key":"2020071612032484900_B84","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0195-27","article-title":"Angiogenesis in cancer, vascular, rheumatoid and other disease.","volume":"1","author":"Folkman","year":"1995","journal-title":"Nat Med"},{"key":"2020071612032484900_B85","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S1470-2045(10)70232-1","article-title":"Biomarkers to predict the clinical efficacy of bevacizumab in cancer.","volume":"11","author":"Jubb","year":"2010","journal-title":"Lancet Oncol"},{"key":"2020071612032484900_B86","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/jncimonographs\/lgr027","article-title":"Assessing early therapeutic response to bevacizumab in primary breast cancer using magnetic resonance imaging and gene expression profiles.","volume":"2011","author":"Mehta","year":"2011","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2020071612032484900_B87","article-title":"Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis","author":"Hirashima","year":"2011","journal-title":"Int J Cancer"},{"key":"2020071612032484900_B88","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1210\/en.2011-2121","article-title":"Animal models and mechanisms of ovarian cancer development.","volume":"153","author":"Richards","year":"2012","journal-title":"Endocrinology"},{"key":"2020071612032484900_B89","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1002\/cncr.11345","article-title":"Pathology and classification of ovarian tumors","volume":"97","author":"Chen","year":"2003","journal-title":"Cancer"},{"key":"2020071612032484900_B90","first-page":"1","article-title":"Natural history and detection of ovarian cancer","volume-title":"Gynecology and obstetrics","author":"Knapp","year":"1988"},{"issue":"26","key":"2020071612032484900_B91","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"issue":"26","key":"2020071612032484900_B92","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/153\/4\/1593\/8977801\/endo1593.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/153\/4\/1593\/8977801\/endo1593.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T18:46:45Z","timestamp":1594925205000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/153\/4\/1593\/2423706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,13]]},"references-count":92,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4,1]]}},"URL":"https:\/\/doi.org\/10.1210\/en.2011-2123","relation":{},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,13]]}}}